The Federal Reserve’s aggressive posture against inflation combined with soaring interest rates have investors taking defensive measures. In effect, Charles River is a tax on the entire biotech industry, with their consistent postings of compounded earnings per share growth rate in the teens since the turn of the century. Keysight sprung up originally as Hewlett-Packard‘s Test & Measurement division more than half a century ago, and was ultimately spun off from Agilent (NYSE:A) into its own publicly-traded entity in 2014.